v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2024 |
Sep. 30, 2023 |
Sep. 30, 2024 |
Sep. 30, 2023 |
|
| OPERATING EXPENSES | ||||
| General and administrative expenses | $ 1,161,090 | $ 661,572 | $ 3,158,525 | $ 1,677,078 |
| Research and development | 414,639 | 49,132 | 894,200 | 285,204 |
| Professional fees | 472,604 | 581,022 | 1,693,676 | 1,021,187 |
| Total operating expenses | 2,048,333 | 1,291,726 | 5,746,401 | 2,983,469 |
| NET LOSS FROM OPERATIONS | (2,048,333) | (1,291,726) | (5,746,401) | (2,983,469) |
| OTHER (EXPENSE) INCOME | ||||
| Interest expense | (39,019) | (130,006) | (678,427) | (358,171) |
| Other income | 29,606 | 33,133 | ||
| Gain on default judgement | 363,091 | 363,091 | ||
| Total other (expense) income | 353,678 | (130,006) | (282,203) | (358,171) |
| Net loss before provision for income taxes | (1,694,655) | (1,421,732) | (6,028,604) | (3,341,640) |
| Provision for income taxes | ||||
| NET LOSS | $ (1,694,655) | $ (1,421,732) | $ (6,028,604) | $ (3,341,640) |
| Net loss per common share - basic and diluted | $ (0.29) | $ (1.44) | $ (1.11) | $ (3.24) |
| Weighted average number of common shares outstanding during the year - basic and diluted | 5,792,293 | 984,516 | 5,420,359 | 1,032,338 |
| X | ||||||||||
- Definition The element represents interest expense on promissory note related party. No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The gain (loss) is the pre-tax difference between the net condemnation award and the entity's adjusted basis of the condemned property. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of revenue and income classified as other. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|